FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
medical research 7 ©Belova59 – pixabay.com Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the…
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
Rani Therapeutics, LLC SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…